ERBB2 and gastric cancer: These complexes demonstrated cytotoxicity comparable to cisplatin and oxaliplatin, and showed selective targeting for HER2-overexpressing NCI-N87 gastric cancer cells and BT-474 breast ductal carcinoma cells, both of which are resistant to apoptosis.